United Therapeutics Co. (UTHR) Given “Underperform” Rating at Jefferies Group LLC
Jefferies Group LLC reaffirmed their underperform rating on shares of United Therapeutics Co. (NASDAQ:UTHR) in a research report sent to investors on Friday morning. Jefferies Group LLC currently has a $116.00 price objective on the biotechnology company’s stock.
Several other brokerages have also issued reports on UTHR. Wedbush reaffirmed an outperform rating and set a $229.00 target price on shares of United Therapeutics in a research report on Thursday, January 5th. Oppenheimer Holdings Inc. set a $175.00 target price on United Therapeutics and gave the company a buy rating in a research report on Wednesday, February 22nd. Zacks Investment Research lowered United Therapeutics from a buy rating to a hold rating in a research report on Monday, February 27th. Leerink Swann upped their target price on United Therapeutics from $127.00 to $148.00 and gave the company a market perform rating in a research report on Thursday, February 23rd. Finally, Credit Suisse Group AG initiated coverage on United Therapeutics in a research report on Thursday. They set an underperform rating and a $120.00 target price on the stock. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $138.31.
Shares of United Therapeutics (NASDAQ:UTHR) traded up 1.80% on Friday, reaching $141.61. The company’s stock had a trading volume of 1,365,337 shares. United Therapeutics has a 12-month low of $97.52 and a 12-month high of $169.89. The stock has a market cap of $6.37 billion, a PE ratio of 9.29 and a beta of 1.42. The firm has a 50 day moving average price of $155.60 and a 200-day moving average price of $136.69.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 22nd. The biotechnology company reported $4.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.61 by $0.51. United Therapeutics had a return on equity of 41.78% and a net margin of 44.40%. The company had revenue of $409 million for the quarter, compared to analyst estimates of $415.51 million. During the same period in the prior year, the company posted $3.80 EPS. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. Equities research analysts expect that United Therapeutics will post $14.13 EPS for the current year.
Your IP Address:
In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,206 shares of the stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $146.72, for a total transaction of $176,944.32. Following the transaction, the chief executive officer now owns 1,346 shares in the company, valued at $197,485.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,218 shares of the stock in a transaction that occurred on Thursday, December 22nd. The stock was sold at an average price of $140.23, for a total value of $170,800.14. Following the transaction, the chief executive officer now owns 1,358 shares in the company, valued at approximately $190,432.34. The disclosure for this sale can be found here. Insiders sold 14,641 shares of company stock worth $2,131,466 in the last 90 days. Company insiders own 7.50% of the company’s stock.
A number of institutional investors have recently modified their holdings of UTHR. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund acquired a new position in shares of United Therapeutics during the third quarter worth about $291,000. Boston Advisors LLC increased its position in shares of United Therapeutics by 152.9% in the third quarter. Boston Advisors LLC now owns 9,345 shares of the biotechnology company’s stock worth $1,103,000 after buying an additional 5,650 shares in the last quarter. Dock Street Asset Management Inc. acquired a new position in shares of United Therapeutics during the third quarter worth about $3,416,000. Acadian Asset Management LLC increased its position in shares of United Therapeutics by 8.5% in the third quarter. Acadian Asset Management LLC now owns 1,271,519 shares of the biotechnology company’s stock worth $150,143,000 after buying an additional 99,249 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its position in shares of United Therapeutics by 43,982.4% in the third quarter. Meeder Asset Management Inc. now owns 7,494 shares of the biotechnology company’s stock worth $884,000 after buying an additional 7,477 shares in the last quarter.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.